Skip to main content
LQDA
NASDAQ Life Sciences

Liquidia Q3: YUTREPIA Sales Hit $222.7M, $389.7M UTC Settlement Charge Drives $236.3M Net Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$47.4
Mkt Cap
$4.285B
52W Low
$22.31
52W High
$93.61
52W Position info
112% above low
Off High info
49% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $22.31.

Summary

Liquidia's Q3 2026 10-Q shows YUTREPIA product sales of $222.7 million and a $389.7 million litigation settlement charge that drove a $236.3 million net loss, with $396.1 million of cash of which $105.4 million is restricted as collateral for the UTC letters of credit.


Key Events · Earnings and Guidance · LQDA

  • YUTREPIA Sales Reach $222.7M in Q3

    Product sales, net were $222.7 million for the three months ended September 30, 2026 versus $51.7 million a year earlier, a $171.0 million increase on higher volume; nine-month sales were $523.0 million versus $58.2 million.

  • $389.7M Settlement Charge Drives Net Loss

    The quarter includes a $389.7 million litigation settlement charge (net cash to be paid of $380.7 million), producing a net loss of $236.3 million, or $2.64 per share, versus a $3.5 million loss a year ago.

  • Cash $396.1M, $105.4M Now Restricted

    Cash and cash equivalents were $396.1 million at September 30, 2026; as of October 23, 2026, $105.4 million was legally restricted as collateral for the $145.4 million standby letters of credit securing the remaining UTC installments.

  • HCR Cash Covenant Raised to $45M

    The Seventh Amendment to the HCR agreement, given in exchange for consent to the UTC letters of credit, raised the minimum cash covenant from $15.0 million to $45.0 million with no fees and no change to payment terms.


Analysis · LQDA · Life Sciences

The commercial engine is working: product sales reached $222.7 million versus $51.7 million a year ago. The income statement, however, is dominated by the one-time $389.7 million litigation settlement charge tied to the October UTC deal, which produced a $236.3 million net loss and a $2.64 per-share loss. The balance sheet tells the more important story. Cash stood at $396.1 million on September 30, but $105.4 million of that is now legally restricted as collateral for the $145.4 million letters of credit securing the two remaining $72.7 million UTC installments due January 31 and April 30, 2027. In exchange for consenting to those letters of credit, HCR raised its minimum cash covenant from $15.0 million to $45.0 million, tightening the liquidity cushion. The settlement also strips YUTREPIA of its PH-ILD label and promotion, so the durability of the current sales run-rate is the open question management itself flags as uncertain.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $47.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $22.31 to $93.61. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $47.20 info
Change: -$2.80 (-6%) info
Market Cap: $4.285B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $47.20 info
Change: +$7.70 (+19%) info
Market Cap: $4.285B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $47.20 info
Change: +$15.44 (+49%) info
Market Cap: $4.285B info
LQDA
Oct 02, 2026, 11:47 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $27.77
Real-time Price: $47.20 info
Change: +$19.43 (+70%) info
Market Cap: $4.285B info
LQDA
Oct 01, 2026, 12:03 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $26.22
Real-time Price: $47.20 info
Change: +$20.98 (+80%) info
Market Cap: $4.285B info